Nuvectis replenishes coffers after Haisco deal with USD 100m public offering

New Jersey-based Nuvectis Pharma, Inc. (Nasdaq: NVCT) [announced](https://www.globenewswire.com/news-release/2026/06/30/3319364/0/en/Nuvectis-Pharma-Announces-Pricing-of-100-Million-Public-Offering-of-Common-Stock.html) priced a USD 100 million underwritten public offering to fund development of three clinical-stage programs acquired through its June 2026 licensing agreement with Haisco Pharmaceutical Group. The financing follows a strategic shift toward complement-mediated rare diseases and oncology and will support a USD 40 million upfront payment [under the recent Haisco transaction](https://app.allsci.com/news/ASC-NR-0000003838754-1.0-1782196542?query=Nuvectis)as well as continued clinical development. The offering comprises 5 million shares priced at USD 20.00 per share, with Cantor Fitzgerald acting as sole bookrunner and six co-managers including H.C. Wainwright & Co. and Roth Capital Partners. Nuvectis has granted underwriters a 30-day option to purchase up to 750,000 additional shares at the offering price, which would bring total gross proceeds to approximately USD 115 million if exercised in full. No warrants were included. Proceeds are allocated to advancing NXP100, NXP200, and NXP900, along with personnel costs and general corporate purposes. At the time of the offering, the company held USD 25.1 million in cash as of March 31, 2026, based on its Q1 2026 financial results, making the USD 100 million raise a material increase in its operating runway. The Haisco transaction transformed Nuvectis's pipeline by adding NXP100, a Phase III-ready oral factor B inhibitor for paroxysmal nocturnal hemoglobinuria, and NXP200, a brain-penetrant BRAF inhibitor for solid tumors, alongside existing clinical-stage SRC inhibitor NXP900. Together, the assets broaden the company's focus beyond oncology into complement-mediated diseases and provide multiple near-term clinical catalysts. NXP900 is an oral small molecule inhibitor of the SRC family of kinases, including SRC and YES1, designed to suppress both catalytic and scaffolding functions of the SRC pathway. The compound has completed Phase I dose escalation and a drug-drug interaction study in healthy volunteers. A [Phase Ib program](https://clinicaltrials.gov/study/NCT05873686?term=NXP900\&viewType=Card\&rank=2) is ongoing, with arms evaluating NXP900 as monotherapy in molecularly defined solid tumors and in combination with osimertinib in EGFR-mutated NSCLC. Management has indicated a preliminary data readout from the Phase Ib study is expected in the summer of 2026. Three NXP900 presentations were accepted at AACR 2026, including preclinical data supporting a combination with sotorasib in KRAS-mutated NSCLC models. The financing follows Nuvectis's USD 13.5 million public offering in 2025 and reflects a substantially higher valuation following the Haisco transaction. The proceeds will fund the license upfront payment and extend the company's operating runway as it advances its expanded pipeline. *** This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: [https://allsci.com/news/](https://allsci.com/news/) --- Spot something wrong? [Report an issue with this article](https://newsgen-prod.reframedata.com/feedback/nuvectis-funding-oncology-raises-usd-100m-to)